Complement-Based Drug Development Summit leaderboard
  • Wednesday, September 30, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 21

Author

Pharma Journalist 9091 posts 0 comments

Haisco Licenses Two Drug Candidates to Nuvectis

Jun 24, 2026
Haisco Pharmaceutical Group has signed an exclusive licensing agreement with U.S.-based biotechnology company Nuvectis, granting the company rights to develop and commercialize two of…
Read More...

Combotope, Boehringer Partner on Cancer Antibody Research

Jun 24, 2026
Combotope Therapeutics has entered into a strategic research collaboration with Boehringer Ingelheim to develop a new generation of tumor-selective antibody therapies for cancer. The…
Read More...

Abbisko, Lilly Expand Drug Discovery Partnership

Jun 24, 2026
Abbisko Therapeutics has entered into a new strategic research collaboration and license agreement with Eli Lilly and Company to discover and develop innovative medicines across…
Read More...

Boehringer Advances Phase III Cancer Precision Medicine Trials

Jun 23, 2026
Boehringer Ingelheim has announced the launch of three Phase III clinical trials aimed at advancing precision oncology for patients with some of the most aggressive forms of cancer. The…
Read More...

Voro and Alloy Partner on Safer Cancer Immunotherapies

Jun 19, 2026
Voro Therapeutics and Alloy Therapeutics have entered into a strategic research collaboration aimed at developing a new generation of cancer immunotherapies designed to improve the…
Read More...

uniQure Reports Early Promise for Epilepsy Gene Therapy

Jun 19, 2026
uniQure has reported encouraging early clinical results from its experimental gene therapy AMT-260, offering new hope for patients living with refractory mesial temporal lobe epilepsy…
Read More...

Boltz and Takeda Expand AI-Powered Drug Discovery Efforts

Jun 19, 2026
Boltz PBC, an applied artificial intelligence research company focused on biomolecular modeling, has announced a new collaboration with Takeda aimed at bringing advanced AI-driven tools…
Read More...

SK Pharmteco Partners With OTXL for Rare Disease Therapies

Jun 19, 2026
SK pharmteco has entered into a new strategic collaboration with the Orphan Therapeutics Accelerator (OTXL), a non-profit biotechnology organization focused on advancing stalled rare…
Read More...

Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Jun 18, 2026
The success of GLP-1 medicines has changed the way healthcare professionals view obesity and metabolic diseases. Over the past few years, drugs such as semaglutide and tirzepatide have…
Read More...

AI-Designed Drug Candidates Enter Clinical Trials: A New Era for Drug Discovery

Jun 18, 2026
The pharmaceutical industry is entering a new chapter as artificial intelligence (AI) begins to play a larger role in drug discovery and development. What once seemed like a futuristic…
Read More...
Prev Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Semaglutide 2 mg Linked to Lower Cardiovascular Risk in Diabetes
  • Novo Nordisk Licenses HRS-1596 for Weekly Oral GLP-1 Therapy
  • AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
  • Tolerance Bio Licenses TLB-33 to Expand Thymic Health Pipeline
  • Direct RNA Binding Emerges as a Powerful Approach for Functional Disease Modulation

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.